Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZAP70 | P43403 | 18/20 | 0.58 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | LYN | P07948 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.40 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | TEK | Q02763 | 1/20 | 0.40 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12795288 | 1.00 | ZAP70 (0.58) | ZAP70SYKABL1LCKLYN | |
| SCHEMBL12794991 | 0.90 | ZAP70 (0.62) | ZAP70SYKABL1LCKLYN | |
| SCHEMBL1158509 | 0.90 | ZAP70 (0.62) | ZAP70SYKABL1LCKLYN | |
| SCHEMBL12794978 | 0.90 | ZAP70 (0.62) | ZAP70SYKABL1LCKLYN | |
| SCHEMBL12795292 | 0.89 | ZAP70 (0.53) | ZAP70SYKABL1LCKLYN | |
| SCHEMBL1158667 | 0.89 | ZAP70 (0.53) | ZAP70SYKABL1LCKLYN | |
| SCHEMBL12794986 | 0.85 | ZAP70 (0.73) | ZAP70SYK | |
| SCHEMBL1160013 | 0.85 | ZAP70 (0.73) | ZAP70SYK | |
| SCHEMBL6525176 | 0.85 | ZAP70 (0.73) | ZAP70SYK | |
| SCHEMBL6525151 | 0.85 | ZAP70 (0.52) | ZAP70SYKABL1LCKLYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053897-A1 | COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS | IRM LLC (BM) | 2011-03-03 | — | — | US | claimed |
| EP-2459556-A1 | 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS | IRM LLC (BM) | 2012-06-06 | — | — | EP | disclosed |
| US-20110053897-A1 | COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS | IRM LLC (BM) | 2011-03-03 | — | — | US | disclosed |
| WO-2011014515-A1 | 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS | IRM LLC (BM) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053897-A1 | COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS | SYK, BTK, LYN | ZAP70 5/4885SYK 1/4885ABL1 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.